SOURCE: Market Foundations Inc.

February 07, 2012 09:00 ET

Perception, Opportunity in Volatility - Research & Analysis on Dendreon Corporation and BioSante Pharmaceuticals, Inc.

HONG KONG--(Marketwire - Feb 7, 2012) - This morning, announced new reports highlighting Dendreon Corporation (NASDAQ: DNDN) and BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX). Free research downloads are available at

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Market Foundations is releasing new coverage on Dendreon Corporation for its current position within the healthcare industry. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. The full research report on Dendreon Corporation (NASDAQ: DNDN) is available here:

Market Foundations has released research on BioSante Pharmaceuticals, Inc. for its changing role within the healthcare industry. BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante products for female sexual health, menopause, contraception and male hypogonadism include its gel formulations of estradiol or testosterone and combinations of estrogen, progestogen and androgen. The full research report on BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) is available here:

About Market Foundations
By providing members with financial information services, we provide the foundation investors need to build investing intelligence. The difference between consistently making good investments or bad investments is nothing more than the right information at the right time.

Contact Information